BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Menzfeld C, John M, van Rossum D, Regen T, Scheffel J, Janova H, Götz A, Ribes S, Nau R, Borisch A, Boutin P, Neumann K, Bremes V, Wienands J, Reichardt HM, Lühder F, Tischner D, Waetzig V, Herdegen T, Teismann P, Greig I, Müller M, Pukrop T, Mildner A, Kettenmann H, Brück W, Prinz M, Rotshenker S, Weber MS, Hanisch UK. Tyrphostin AG126 exerts neuroprotection in CNS inflammation by a dual mechanism. Glia 2015;63:1083-99. [PMID: 25731696 DOI: 10.1002/glia.22803] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Pinke KH, Zorzella-Pezavento SFG, Lara VS, Sartori A. Should mast cells be considered therapeutic targets in multiple sclerosis? Neural Regen Res 2020;15:1995-2007. [PMID: 32394947 DOI: 10.4103/1673-5374.282238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Meier UC, Cipian RC, Karimi A, Ramasamy R, Middeldorp JM. Cumulative Roles for Epstein-Barr Virus, Human Endogenous Retroviruses, and Human Herpes Virus-6 in Driving an Inflammatory Cascade Underlying MS Pathogenesis. Front Immunol 2021;12:757302. [PMID: 34790199 DOI: 10.3389/fimmu.2021.757302] [Reference Citation Analysis]
3 Choi JY, Yun J, Hwang CJ, Lee HP, Kim HD, Chun H, Park PH, Choi DY, Han SB, Hong JT. (E)-2-methoxy-4-(3-(4-methoxyphenyl) prop-1-en-1-yl) Phenol Ameliorates MPTP-Induced Dopaminergic Neurodegeneration by Inhibiting the STAT3 Pathway. Int J Mol Sci 2019;20:E2632. [PMID: 31146332 DOI: 10.3390/ijms20112632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alshammari MA, Attia SM. Protection by tyrosine kinase inhibitor, tyrphostin AG126, through the suppression of IL-17A, RORγt, and T-bet signaling, in the BTBR mouse model of autism. Brain Research Bulletin 2018;142:328-37. [DOI: 10.1016/j.brainresbull.2018.08.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Kaviarasi S, Yuba E, Harada A, Krishnan UM. Emerging paradigms in nanotechnology for imaging and treatment of cerebral ischemia. Journal of Controlled Release 2019;300:22-45. [DOI: 10.1016/j.jconrel.2019.02.031] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
6 Ahmad SF, Ansari MA, Nadeem A, Bakheet SA, Alsanea S, Al-Hosaini KA, Mahmood HM, Alzahrani MZ, Attia SM. Inhibition of tyrosine kinase signaling by tyrphostin AG126 downregulates the IL-21/IL-21R and JAK/STAT pathway in the BTBR mouse model of autism. Neurotoxicology 2020;77:1-11. [PMID: 31811869 DOI: 10.1016/j.neuro.2019.12.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Carnero Contentti E, Correale J. Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis. Expert Opin Emerg Drugs 2020;25:377-81. [PMID: 32910702 DOI: 10.1080/14728214.2020.1822817] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Geladaris A, Häusler D, Weber MS. Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression? Int J Mol Sci 2021;22:3461. [PMID: 33801644 DOI: 10.3390/ijms22073461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 García-Merino A. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy. Cells 2021;10:2560. [PMID: 34685540 DOI: 10.3390/cells10102560] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Almalki WH, Alghamdi S, Alzahrani A, Zhang W. Emerging paradigms in treating cerebral infarction with nanotheranostics: opportunities and clinical challenges. Drug Discov Today 2021;26:826-35. [PMID: 33383212 DOI: 10.1016/j.drudis.2020.12.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Pryce G, Baker D. Oligoclonal bands in multiple sclerosis; Functional significance and therapeutic implications. Does the specificity matter? Multiple Sclerosis and Related Disorders 2018;25:131-7. [DOI: 10.1016/j.msard.2018.07.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
12 Giovannoni G, Popescu V, Wuerfel J, Hellwig K, Iacobeus E, Jensen MB, García-domínguez JM, Sousa L, De Rossi N, Hupperts R, Fenu G, Bodini B, Kuusisto H, Stankoff B, Lycke J, Airas L, Granziera C, Scalfari A. Smouldering multiple sclerosis: the ‘real MS’. Ther Adv Neurol Disord 2022;15:175628642110667. [DOI: 10.1177/17562864211066751] [Reference Citation Analysis]
13 Häusser-Kinzel S, Weber MS. The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. Front Immunol 2019;10:201. [PMID: 30800132 DOI: 10.3389/fimmu.2019.00201] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
14 Martin E, Aigrot MS, Grenningloh R, Stankoff B, Lubetzki C, Boschert U, Zalc B. Bruton's Tyrosine Kinase Inhibition Promotes Myelin Repair. Brain Plast 2020;5:123-33. [PMID: 33282676 DOI: 10.3233/BPL-200100] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]